Under the Licensing and Supply Agreement signed by both companies, Lupin will have semi-exclusive rights to co-market Zydus’ ...

Dr. Reddy's, Sun Pharma, Zydus & others launch branded generics after patent expiry, targeting a ₹12,000-crore market ...

Global pharma major Lupin Limited (Lupin) has entered into a Licensing and Supply Agreement with Zydus Lifesciences Limited ...

FILE PHOTO: The logo of Lupin, India's No. 2 drugmaker, is seen on the facade of its pharmaceutical plant in Verna FILE PHOTO: The logo of Lupin, India's No. 2 drugmaker, is seen on the facade of its ...

Pharma stocks rose up to 4% as Novo Nordisk’s semaglutide patent nears expiry, raising expectations of cheaper generics in ...

March 17 () - Indian drugmakers Zydus Lifesciences and Lupin have signed a licensing and supply ‌deal on Tuesday to co‑market ...

Lupin management remains confident that the India formulations business will continue to outperform IPM by 1.2-1.3 times, supported by strong sales force and pipeline of new product launches.

Global pharmaceutical firm Lupin will expand its Florida operations with a a new manufacturing plant in Coral Springs. With a projected cumulative investment of $250 million, including research & ...

Zydus Lifesciences and Lupin have joined forces to bring Semaglutide Injection to India. This medication helps manage type 2 ...

Catalyst Pharmaceuticals (NASDAQ:CPRX) said that the company and licensor SERB S.A. signed a settlement agreement with Lupin Pharmaceuticals, putting an end to a patent lawsuit. The lawsuit was in ...

Dharmesh Kant, Head of Research at Chola Securities said pharma remains a strong sector with consistent earnings, ...